Kazakhstan Medical Device Registration Exemptions: Union List and National Channels
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Kazakhstan’s exemptions from registration come from two levels: the exemption list in Article 4 of the 2014 Agreement at Union level, and national Kazakh channels for specific purposes such as exhibition samples, research prototypes, emergency life-saving treatment and exceptional use of unregistered devices. The protocol signed on February 9, 2026 added four categories of exemptions at Union level: custom-made devices manufactured to the order of an individual patient, devices imported under competent authority permission to save lives, devices manufactured within a member state exclusively for export, and combination packs and first-aid kits composed of registered devices together with medicines. An exemption does not mean an absence of supervision: every channel carries explicit purpose restrictions and documentation requirements, and goods admitted under an exemption generally cannot be redirected to ordinary commercial sale. Because the exemption channels and the registration pathway serve different purposes, mixing their documentation or treating an exemption as a low-cost substitute for registration is a direct route to customs and supervisory problems.
2. Legal basis
| Regulation | Reference / number | Date | Provisions |
|---|---|---|---|
| Agreement on the Common Principles and Rules for the Circulation of Medical Devices in the Eurasian Economic Union | Agreement | December 23, 2014 | Article 4 (scope of registration and the list of exemptions) |
| Protocol amending the 2014 Agreement (expanding the list of exemptions) | Protocol | Signed February 9, 2026 | Additional items in Article 4; pending completion of domestic procedures by member states |
| Order of the Minister of Health approving the Rules for the transfer of medicines and medical devices across the customs border of a state and the state service for issuing import and export licences | No. ҚР ДСМ-237/2020 | December 8, 2020 (Ministry of Justice registration No. 21749) | Licence channel for the import of unregistered devices |
| Order of the Minister of Health approving the Rules for the use of medicines and medical devices (unregistered devices) | No. ҚР ДСМ-280/2020 | 2020 | Exceptional use of unregistered devices |
| Order of the Minister of Health approving the Rules for State Registration, Re-registration and Variations to Registration Dossiers of Medicines and Medical Devices | No. ҚР ДСМ-16 | February 9, 2021 | Scope of registration |
3. Expert insights
Insight one: the exemption list operates by enumeration, so anything not listed requires registration. The list works by item-by-item enumeration, which means the decision method is comparison, not inference. When evaluating a new product, compare it against each item of the most recent version of the list rather than relying on the experience that a similar product was once exempted. A close-but-not-identical product is not exempt, and a precedent created under an older version of the list does not survive an amendment. GRZAN records the comparison row by row and keeps it in the project file as the basis for the scoping conclusion.
Insight two: the custom-made device exemption is strictly limited to the person and the order. Only devices manufactured to the order of an individual patient and intended solely for that patient’s personal use fall within the exemption. Products manufactured in batches and then configured to patient parameters do not qualify as custom-made devices and still require registration. The distinction turns on when the specification is fixed: in genuine custom manufacture the specification exists only because of the individual order, whereas in batch production with configuration the specification already exists and the patient merely selects among options.
Insight three: the export-only exemption is for manufacturers located within member states. Devices manufactured within a member state and exclusively for export are exempt from Union registration. This provision offers limited direct value to manufacturers based outside the Union, but it becomes relevant when structuring production and registration arrangements with local partners in Kazakhstan, because a locally based line dedicated to export markets can operate without Union registration while the same product sold domestically cannot.
Insight four: the import and use of unregistered devices in Kazakhstan runs on separate channels. Order No. ҚР ДСМ-237/2020 provides the state service for licences to import unregistered medicines and medical devices, while Order No. ҚР ДСМ-280/2020 governs the exceptional use of unregistered devices. Exhibition samples, research prototypes and emergency life-saving treatment each carry their own documentation requirements, and the same set of papers cannot be reused across the three situations. Preparing per-channel files from the start avoids rejections at the licence stage.
Insight five: the protocol of February 9, 2026 is pending completion of domestic procedures by member states. The protocol is signed but its status of application depends on each member state’s ratification progress. In Kazakhstan projects, any reliance on the newly added exemption categories must be accompanied by verification of the protocol’s status of application in Kazakhstan, which remains pending verification until national procedures conclude.
4. Practical recommendations
- At project initiation, compare the product against the latest version of the exemption list item by item and keep the comparison record.
- In the justification file for a custom-made device, state both required elements explicitly: manufacture to the order of an individual patient, and use solely for that patient.
- Prepare the exhibition sample, research prototype and emergency treatment channels separately, stating the purpose and the disposal method in each application.
- Before relying on any new exemption category introduced by the protocol of February 9, 2026, verify its status of application in Kazakhstan.
- Devices imported under an exemption must not be diverted to sale; state the disposal method in the application material and keep records of the actual disposal afterwards.
5. Verification checklist
- □ The latest version of the exemption list has been compared item by item and the comparison record is retained
- □ For custom-made devices, the elements of individual patient order and personal use only are stated in the justification
- □ Import of unregistered devices is licensed under Order No. ҚР ДСМ-237/2020
- □ Use of unregistered devices conforms to the exceptional situations in Order No. ҚР ДСМ-280/2020
- □ The status of application of the protocol of February 9, 2026 in Kazakhstan has been verified
- □ The purpose and disposal method of exemption-imported devices are documented and traceable
GRZAN provides registration support in Kazakhstan for manufacturers, importers and authorized representatives, covering exemption analysis, licence applications and customs documentation. For assistance, contact info@grzanglobal.com.
Regulatory information verified as of October 29, 2026.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us